FAQ

Q：What is the corporate policy?

A：Our corporate policy is that we are committed to contributing to global healthcare with our cutting-edge antibody technologies.

Q：How was the Company established?

A：The Company was established aiming to utilize antibodies against diagnosis and drug discovery targets for healthcare, based on expressing protein and antibody generating technologies developed by LSBM, Research Center for Advanced Science and Technology, the University of Tokyo.
As for details, please refer to “About us”.

Q：What fields of business does the Company develop?

A: We develop business in the three fields; antibody drug discovery, antibody research support service, and antibody/reagent sales.
Please refer to the “Business” for details.

Q：When did the Company go public?

A：June 22, 2021.

Q：What is the origin of the company name?

A：“Perseus” comes from a great hero in a Greek myth. “Proteomics” means the research on structures and functions of protein. Perseus is said to have killed Medusa and to have saved Andromeda from Tiamat, a sea monster, by showing it Medusa’s head. We compare the arms he used for defeating Tiamat including Pegasus and Medusa’s head to our antibody technologies. The Company name represents our mission to save patients (Andromeda) by fighting cancers and other diseases which are difficult to cure (Tiamat).

Q：Where can I find the latest business results?

A：Visit "Financial Results" or "Financial Highlights" on our website. We also provide “Presentation Materials” every six months.

Q：When is your fiscal year-end?

A：Our fiscal year ends on March 31 and the first half ends on September 30. We announce the year-end business results in May, and quarterly results in August, November, and February.

Q：Where can I find the latest Summary of the Financial results？

A：Please refer to the "Financial Results"  in the IR Library.

Q：Where are your stocks listed?

A：On the Growth Market of Tokyo Stock Exchange.

Q：What is the securities code number?

A：4882.

Q：What is the stock trading unit of Perseus Proteomics?

A：1 trading unit is 100 shares.

Q：What is your dividend policy?

A：We recognize profit return to shareholders as an important issue in management, however, we have not been able to pay dividend so far. Development of medical drugs requires big upfront investment and long-range period. Therefore, we strive to increase internal reserve and prioritize in securing R&D expenses for a while. When we can distribute dividends, basically we make payments annually after approval at a general shareholders’ meeting. We can also distribute interim dividends by the resolution of a Board of Directors for swift payments as stipulated in the Articles of Incorporation pursuant to the Paragraph 5, Article 454 of the Companies Act.

Q：How can I purchase Perseus Proteomics stocks?

A：Please contact securities company about the detail.

Q：How much is the stock price of Perseus Proteomics?

A：Please click here.

Q：Who is the shareholder registry administrator for Perseus Proteomics?

A：Mitsubishi UFJ Trust Bank.

Q：How can I transfer stock or change the address on my shareholder account?

A：Please contact the securities company where you have an account.

Q：When is a general shareholders meeting held?

A：A general shareholders meeting is held in the end of June every year. We will notice the date, venue and other information in late May or early June on this website.

Q：How do I exercise my voting right at a shareholders’ meeting?

A：We send a convocation notice and a voting form to the shareholders listed in the Shareholders Registry at the end of the record date (March 31). Shareholders can exercise the voting rights by:

• attending the shareholders’ meeting bringing with the execution form.
• electronic voting.
• returning the voting form after indicating your approval or disapproval of each proposal by post.

Q：Do you have any mailings such as shareholder communications and interim financial statements? If so, when are they mailed？

A：We do not send interim financial statements by mail. In addition, we do not create shareholder communications. This is because the main information is on the Company's website, but also helps resource conservation. Thank you for your understanding.

Q: Some biotech ventures conduct even a phase 3 clinical trial in house.  Is there any reason why you finish the development of PPMX-T003 for PV treatment at the phase 1 completion?

A: Conventionally, out-licensing agreements at early stage are often seen, however, it has become more common to conduct up to Phase 1 clinical trials before agreements, and as you mentioned, out-licensing after Phase 2 or Phase 3 trials is also seen.  The stage of clinical trials conducted depends on the strategies and circumstances of each company.  Depending on the target disease, completing a Phase 3 trial in-house and obtaining approval can maximize revenue, however, it also involves significant risks and development costs.  Besides, the necessary number of cases and trial costs vary greatly depending on the disease.  In particular, for Phase 3 trials, the required number of cases vary to demonstrate statistical advantages due to factors including comparison with existing drugs and variability in symptoms.  On the other hand, the required number of cases are fewer as for the diseases without existing drugs or highly fetal diseases.  We have selected out-licensing after a Phase 1 trial as a result of comprehensive consideration.

Q: Please explain your company’s disclosure policy regarding patents.

A: With respect to each patent application, our basic policy is to disclose the application when we first receive a notice of allowance in any of the major countries or regions, namely Japan, the United States, Europe, or China. If, for the same patent application, a notice of allowance is subsequently issued or the patent is registered in another major country or region, we generally do not make an additional disclosure. However, if we determine that it may have a material impact on our business, R&D pipeline, or corporate value, we will consider the need for disclosure on a case-by-case basis.

Q: What are the differences between Astatine-211 and Actinium-225, the radioisotopes used in radiolabeled-antibody radioimmunotherapy (RIT)? Do these two radioisotopes compete with each other?

A: There are radioactive isotopes (RIs) that emit beta radiation and others that emit alpha radiation. Currently, the development of alpha-emitting radiopharmaceuticals, which are expected to be highly effective, is being actively pursued. Among them, Actinium-225 has become a major focus of development worldwide, following reports of cases in which tumors disappeared in patients with end-stage prostate cancer.
Meanwhile, in Japan, Astatine-211 has attracted attention because it can be produced domestically at relatively low cost. Since Astatine-211 has a half-life of 7.2 hours, which is significantly shorter than that of Actinium-225, research and development is being promoted through collaboration among industry, government, and academia based on the concept of using it immediately after production.
Although Astatine-211 and Actinium-225 have their own advantages and disadvantages, we have decided to focus exclusively on Actinium-225, given our view that Astatine-211 would face significant challenges in terms of global adoption and regulatory development.

Q: PPMX-T003 is currently being developed for aggressive NK-cell leukemia (ANKL).　What is the outlook for expanding its indication to acute myeloid leukemia and lymphoma？　If PPMX-T003 is approved for ANKL, what procedures would be required for such indication expansion, and what would be the expected timeframe?

A: Because drug approvals are granted for each disease or indication, clinical trials are also required for each disease when expanding indications. If a drug has already received marketing approval for one indication, a substantial amount of safety and other relevant information has been accumulated, making it easier to conduct clinical trials for new diseases. However, the time required for clinical trials cannot be stated uniformly, as the dosage and administration may vary by indication, and the number of patients needed for evaluation may also differ.

Q: What characteristics does PPMX-T003, which is being developed for polycythemia vera (PV), have compared with competing drugs?

A: In the treatment of PV, it is necessary to reduce elevated red blood cell levels. Existing treatment strategies generally fall into two categories: reducing hematopoietic stem cells involved in red blood cell production, and reducing the availability of iron needed to produce red blood cells.
The former approach, shown in the left column of the table on page 10 of our financial results presentation for the fiscal year ended March 2025, includes DNA synthesis inhibitors, JAK2 inhibitors, and interferons. These agents are known to be associated with various side effects. For the latter approach, shown in the middle column of the same table, there are currently no approved drug therapies that replace phlebotomy, and hepcidin mimetics and other agents are being developed as new drug candidates to serve as alternatives to phlebotomy.
In contrast, PPMX-T003 has a completely new mechanism of action: it reduces red blood cells by inhibiting iron uptake by erythroblasts, the precursor cells of red blood cells, without reducing circulating iron levels in the body. As a result, it is expected to have fewer side effects, such as those associated with insufficient circulating iron levels.

Q：Which industry sector does the Company belong to?

A：Medical industry.

Q：How can I contact IR group?

A：Select “IR” on “Inquiry” form and send us your inquiry.Please note that, as a rule, we do not respond to individual inquiries. If necessary, we will provide answers via the “Frequently Asked Questions” section on the IR website.

Q:Do you have any plans to release the progress of the clinical trial of PPMX-T003 for ANKL in the future?

A:Since this clinical trial is Investigator Initiated Clinical Trial, we will not proactively disclose the information.

Q: Is there anything you can disclose about the future development plans for PPMX-T003 targeting polycythemia vera?

A: The phase I trial of PPMX-T003 targeting polycythemia vera was completed in June 2024. We are currently conducting out-licensing activities based on the trial results.

Q: Does your company conduct investor relations meetings at its headquarters?

A: We conduct investor relations meetings with analysts and institutional investors at our headquarters.

Q: Does your company publish the details of its financial results briefings on its website?

A: We publish the dates and times of our financial results briefings for analysts on our website. Additionally, we disclose the briefing materials in a timely manner in conjunction with the briefings. Furthermore, we promptly disclose transcripts of the briefings via timely disclosure after they conclude.

Q: Does your company publish minutes of its annual general meeting that include the “start time,” “number of attendees,” “number of questions,” and “questions and answers”?

 

A: We disclose the results of our annual general meeting of shareholders in a timely manner through a notice of resolutions. Please note that this notice does not include the “start time,” “number of attendees,” “number of questions,” or “questions and answers.”

Q: Could you provide further details on the PPMX-T003-CT102 study being conducted as clinical research?

A: This study is led by Dr. Tomoki Ito of the Department of Hematology-Oncology at Kansai Medical University Hospital. It is designed to review the clinical status of patients with polycythemia vera who participated in the Phase 1 trial of PPMX-T003 previously conducted by the Company, including their condition before trial participation and at 3 months, 6 months, 1 year, and 2 years after completion of the trial.
The purpose of this study is to further assess aspects of the potential effects of PPMX-T003 in polycythemia vera that could not be evaluated during the original trial period.
The study is scheduled to be completed on June 30, 2026. At present, the timing of any announcement of results has not been determined. If favorable results are obtained, the findings may be presented at an academic conference or submitted to an academic journal, subject to Dr. Ito’s judgment. Such disclosure would typically take several months after completion of the study.